Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Get Rating)’s share price traded down 5.8% during trading on Monday after Barclays lowered their price target on the stock from $141.00 to $105.00. The company traded as low as $50.05 and last traded at $50.19. 1,361 shares changed hands during trading, a decline of 100% from the average session volume of 540,358 shares. The stock had previously closed at $53.28.
A number of other equities research analysts have also recently weighed in on RARE. Piper Sandler dropped their price objective on Ultragenyx Pharmaceutical from $135.00 to $130.00 and set an “overweight” rating for the company in a research note on Thursday, July 28th. Cowen decreased their price target on Ultragenyx Pharmaceutical from $124.00 to $99.00 in a report on Friday, May 6th. The Goldman Sachs Group reduced their target price on Ultragenyx Pharmaceutical from $139.00 to $101.00 and set a “neutral” rating for the company in a report on Tuesday, May 24th. Stifel Nicolaus reduced their target price on Ultragenyx Pharmaceutical from $176.00 to $142.00 and set a “buy” rating for the company in a report on Friday, July 1st. Finally, StockNews.com cut Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Tuesday, June 21st. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $108.42.
Hedge Funds Weigh In On Ultragenyx Pharmaceutical
A number of large investors have recently bought and sold shares of the business. Wellington Management Group LLP raised its holdings in shares of Ultragenyx Pharmaceutical by 17.1% during the first quarter. Wellington Management Group LLP now owns 3,370,245 shares of the biopharmaceutical company’s stock valued at $244,747,000 after buying an additional 492,842 shares during the last quarter. Suvretta Capital Management LLC acquired a new position in shares of Ultragenyx Pharmaceutical during the fourth quarter valued at approximately $40,804,000. State Street Corp increased its stake in shares of Ultragenyx Pharmaceutical by 16.1% during the first quarter. State Street Corp now owns 1,948,684 shares of the biopharmaceutical company’s stock valued at $141,513,000 after acquiring an additional 269,843 shares during the period. Goldman Sachs Group Inc. grew its position in Ultragenyx Pharmaceutical by 43.4% in the fourth quarter. Goldman Sachs Group Inc. now owns 725,678 shares of the biopharmaceutical company’s stock worth $61,023,000 after buying an additional 219,470 shares during the last quarter. Finally, Marshall Wace LLP grew its position in Ultragenyx Pharmaceutical by 682.3% in the fourth quarter. Marshall Wace LLP now owns 234,230 shares of the biopharmaceutical company’s stock worth $19,697,000 after buying an additional 204,288 shares during the last quarter. Institutional investors own 97.49% of the company’s stock.
Ultragenyx Pharmaceutical Stock Up 1.3 %
The company’s 50-day simple moving average is $55.17 and its 200-day simple moving average is $63.67. The stock has a market cap of $3.59 billion, a price-to-earnings ratio of -7.01 and a beta of 1.22.
Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Rating) last issued its earnings results on Thursday, July 28th. The biopharmaceutical company reported ($2.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.72) by ($0.54). The company had revenue of $89.34 million for the quarter, compared to analyst estimates of $87.33 million. Ultragenyx Pharmaceutical had a negative net margin of 151.34% and a negative return on equity of 57.22%. The company’s quarterly revenue was up 2.7% on a year-over-year basis. During the same period last year, the business earned ($1.45) EPS. As a group, analysts expect that Ultragenyx Pharmaceutical Inc. will post -7.23 EPS for the current fiscal year.
Ultragenyx Pharmaceutical Company Profile
Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.
